SoftServe Acquires Hoverstate
7.6.2023 16:01:00 EEST | Business Wire | Press release
SoftServe, a global IT consulting firm, today announced its acquisition of Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. The acquisition positions both companies as a single software solution source for digital native organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005221/en/
SoftServe, a global IT consulting firm, has announced acquiring Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. (Graphic: Business Wire)
SoftServe’s dynamic offerings and global footprint enhance Hoverstate’s intelligent process automation expertise and its key partnership with the Pega Platform from Pegasystems, the low-code platform provider empowering the world’s leading enterprises to Build for Change®. Clients now have deeper access to accelerated cloud-based digital processes and increased developmental efficiencies using data and analytics, AI/ML, and experience-based software engineering.
“As a SoftServe company, Hoverstate expands our suite of innovative services to help our clients streamline processes and minimize costs in today’s macroeconomic environment,” said Chris Baker, SoftServe CEO. “Hoverstate takes a human-centric approach that results in amazing user experiences and robust business outcomes that will be amplified across SoftServe’s clients and prospects.”
Hoverstate is already known for helping companies improve customer service, deepen engagement, and reduce operating costs by up to 50% across industries. The acquisition reinforces and extends SoftServe’s industry expertise in the healthcare, life science, banking, financial services, transportation, and logistics sectors. It also further amplifies Hoverstate’s status as a Specialized Pega Partner for the platform’s solutions to a global client marketplace.
Hoverstate’s expertise with the Pega Platform accelerates the cost optimization associated with back-office process transformation. Their reputational design-driven approach to the front-end ensures deeper customer engagement. Further, Hoverstate brings marquee healthcare organizations to SoftServe's client list. These organizations will accelerate business outcomes by leveraging their existing investments in technology solutions provided by Amazon Web Services, Google, Microsoft, NVIDIA, and SiteCore. Hoverstate’s holistic methodology enhanced by SoftServe’s AI/ML and advisory capabilities will create profound business outcomes for clients.
SoftServe has more than 12,000 associates spanning 14 countries in North America, EMEA, APAC, and Latin America. Along with Hoverstate’s footprint in offices across the U.S. and Italy, Hoverstate Chief Strategy Officer and Managing Partner Rob Fauver will accompany Chief Innovation Officer and Managing Partner Kyung Ahn as part of the SoftServe family.
“We believe joining a strong digital transformation services provider is the best path to deliver increased capabilities and exceptional digital solutions to our clients,” Fauver said. “SoftServe shares our people-first values. The cultural synergies between the firms are unmatched. SoftServe’s global delivery network gets us closer to our clients. It makes our support agile and scalable. We’re ready for the future.”
To learn more about SoftServe acquiring Hoverstate, please visit this webpage.
ABOUT SOFTSERVE
SoftServe is a leading IT consulting company transforming and optimizing how enterprises and software companies do business. Our end-to-end approach assures innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
ABOUT HOVERSTATE
Hoverstate is a full-service digital agency focusing on digital strategy, mobile apps, web development and business applications with a deep expertise in the health insurance, pharmaceutical, and life sciences industries. The main capabilities are: AppDev, Service Design/CX/UX, UI, DevOps & Infrastructure, Big Data, AI/ML, RPA, Consultancy across primarily Healthcare and Media, Education, Financial Services verticals.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005221/en/
Contact information
Kayla Cash
Public Relations Manager
SoftServe, Inc.
kcash@softserveinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom